SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

被引：0

作者：

Constanze Schneider

Thomas Oellerich

Hanna-Mari Baldauf

Sarah-Marie Schwarz

Dominique Thomas

Robert Flick

Hanibal Bohnenberger

Lars Kaderali

Lena Stegmann

Anjali Cremer

Margarethe Martin

Julian Lohmeyer

Martin Michaelis

Veit Hornung

Christoph Schliemann

Wolfgang E Berdel

Wolfgang Hartmann

Eva Wardelmann

Federico Comoglio

Martin-Leo Hansmann

Alexander F Yakunin

Gerd Geisslinger

Philipp Ströbel

Nerea Ferreirós

Hubert Serve

Oliver T Keppler

Jindrich Cinatl

机构：

[1] Institute of Medical Virology,Department of Medicine II

[2] University of Frankfurt,Cambridge University Department of Haematology

[3] Hematology and Oncology,Department of Virology

[4] ,Department of Chemical Engineering and Applied Chemistry

[5] Goethe University of Frankfurt,Gene Center and Department of Biochemistry

[6] Cambridge Institute of Medical Research,Department of Medicine A (Hematology

[7] German Cancer Consortium partner site,undefined

[8] German Cancer Research Center,undefined

[9] Max von Pettenkofer Institute,undefined

[10] Ludwig Maximilian University of Munich,undefined

[11] Pharmazentrum frankfurt/ZAFES,undefined

[12] ,undefined

[13] Institute of Clinical Pharmacology,undefined

[14] Goethe University of Frankfurt,undefined

[15] University of Toronto,undefined

[16] Institute of Pathology,undefined

[17] University Medical Center,undefined

[18] Institute of Bioinformatics,undefined

[19] University Medicine Greifswald,undefined

[20] Centre for Molecular Processing and School of Biosciences,undefined

[21] University of Kent,undefined

[22] Institute of Molecular Medicine,undefined

[23] University Hospital Bonn,undefined

[24] Ludwig Maximilian University of Munich,undefined

[25] Oncology),undefined

[26] University Hospital Münster,undefined

[27] Gerhard Domagk Institute for Pathology,undefined

[28] University Hospital Münster,undefined

[29] Senckenberg Institute of Pathology,undefined

[30] University of Frankfurt,undefined

[31] Fraunhofer Institute for Molecular Biology and Applied Ecology (IME),undefined

[32] Project Group Translational Medicine and Pharmacology (TMP),undefined

来源：

Nature Medicine | 2017年 / 23卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The therapeutic response of acute myeloid leukemia to the nucleoside analog Ara-C is controlled by SAMHD1, an enzyme that hydrolyzes the active metabolite Ara-CTP.

引用

页码：250 / 255

页数：5

共 50 条

[21] Cell-to-Cell Spreading of HIV-1 in Myeloid Target Cells Escapes SAMHD1 Restriction
Xie, Maorong
Leroy, Heloise
Mascarau, Remi
Woottum, Marie
Dupont, Maeva
Ciccone, Camille
Schmitt, Alain
Raynaud-Messina, Brigitte
Verollet, Christel
Bouchet, Jerome
Bracq, Lucie
Benichou, Serge
MBIO, 2019, 10 (06):
[22] Cytarabine Dose for Acute Myeloid Leukemia
Lowenberg, Bob
Pabst, Thomas
Vellenga, Edo
van Putten, Wim
Schouten, Harry C.
Graux, Carlos
Ferrant, Augustin
Sonneveld, Pieter
Biemond, Bart J.
Gratwohl, Alois
de Greef, Georgine E.
Verdonck, Leo F.
Schaafsma, Martijn R.
Gregor, Michael
Theobald, Matthias
Schanz, Urs
Maertens, Johan
Ossenkoppele, Gert J.
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (11): : 1027 - 1036
[23] Cytarabine in relapsed acute myeloid leukemia
Hardesty, Brandon M.
Cripe, Larry D.
LEUKEMIA RESEARCH, 2012, 36 (04) : 387 - 388
[24] Cytarabine Dose for Acute Myeloid Leukemia
Mathisen, Michael S.
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (22): : 2167 - 2167
[25] Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
Rassidakis, George Z.
Herold, Nikolas
Myrberg, Ida Hed
Tsesmetzis, Nikolaos
Rudd, Sean G.
Henter, Jan-Inge
Schaller, Torsten
Ng, Siok-Bian
Chng, Wee Joo
Yan, Benedict
Ng, Chin Hin
Ravandi, Farhad
Andreeff, Michael
Kantarjian, Hagop M.
Medeiros, L. Jeffrey
Xagoraris, Ioanna
Khoury, Joseph D.
BLOOD CANCER JOURNAL, 2018, 8
[26] Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
George Z. Rassidakis
Nikolas Herold
Ida Hed Myrberg
Nikolaos Tsesmetzis
Sean G. Rudd
Jan-Inge Henter
Torsten Schaller
Siok-Bian Ng
Wee Joo Chng
Benedict Yan
Chin Hin Ng
Farhad Ravandi
Michael Andreeff
Hagop M. Kantarjian
L. Jeffrey Medeiros
Ioanna Xagoraris
Joseph D. Khoury
Blood Cancer Journal, 8
[27] mTOR, a new therapeutic target in acute myeloid leukemia
Récher, C
Dos Santos, C
Demur, C
Payrastre, B
CELL CYCLE, 2005, 4 (11) : 1540 - 1549
[28] PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
Pandolfi, Ashley
Stanley, Robert F.
Yu, Yiting
Bartholdy, Boris
Pendurti, Gopichand
Gritsman, Kira
Boultwood, Jacqueline
Chernoff, Jonathan
Verma, Amit
Steidl, Ulrich
BLOOD, 2015, 126 (09) : 1118 - 1127
[29] PARP1 as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome
Kontandreopoulou, Christina-Nefeli
Diamantopoulos, Panagiotis T.
Tiblalexi, Despina
Giannakopoulou, Nefeli
Viniou, Nora-Athina
BLOOD ADVANCES, 2021, 5 (22) : 4794 - 4805
[30] PAK1 Is a Therapeutic Target in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Stanley, Robert
Pandolfi, Ashley
Verma, Amit
Steidl, Ulrich
Chernoff, Jonathan
Yu, Yiting
Boultwood, Jacqueline
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →